Molecular Insight Pharmaceuticals Inc.(MIPI), a biopharmaceutical company focused on discovering and developing targeted therapeutic and imaging radiopharmaceuticals for use in oncology and cardiology, filed for Chapter 11 protection Dec. 9 in the U.S. Bankruptcy Court for the District of Massachusetts (In re Molecular Insight Pharmaceuticals Inc.).
Financing Commitment Achieved.
The Cambridge, Mass.-based company announced Dec. 9 in a news release that it has entered into a $45-million financing commitment from Savitr Capital LLC, to be effected through a corporate reorganization under a Chapter 11 filing. According to the news release, the investment from Savitr Capital would ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.